Allergan clinical trials

Acquired by AbbVie, May 8, 2020 · source ↗

The registry lists 505 studies whose lead sponsor is Allergan. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Jun 1, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 505. List all 505 → · All AbbVie studies →

• A Study to Assess Adverse Events and Change in Disease Activity of HArmonyCa Lidocaine Injectable Gel for Mid Face Soft Tissue Augmentation in Adult ParticipantsCompletedNCT05452070Phase 3

  Sponsor listed in the registry: Allergan · First submitted after Allergan became part of AbbVie

• A Study to the Assess the Change in Condition and Adverse Events of OnabotulinumtoxinA X Injection in Adult Participants With Glabellar LinesCompletedNCT05100199Phase 2

  Sponsor listed in the registry: Allergan · First submitted after Allergan became part of AbbVie

• 18 Month Prospective Efficacy and Safety Study of Bimatoprost Intracameral Implant (DURYSTA)CompletedNCT04647214

  Sponsor listed in the registry: Allergan · First submitted after Allergan became part of AbbVie

• Safety Follow-up Study in Subjects With Silicone Gel-filled Breast Implants as Compared Both to Saline-filled Breast Implants and to National NormsActive, not recruitingNCT00443274

  Sponsor listed in the registry: Allergan · First submitted before Allergan became part of AbbVie

• A Study To Assess the Adverse Effects and Change in Condition of OnabotulinumtoxinA X Injection in Adult Participants With Forehead LinesCompletedNCT05152576Phase 2

  Sponsor listed in the registry: Allergan · First submitted after Allergan became part of AbbVie

• A Study of OnabotulinumtoxinA X Injection in Adult Participants With Glabellar LinesCompletedNCT05013424Phase 2

  Sponsor listed in the registry: Allergan · First submitted after Allergan became part of AbbVie

• Study to Evaluate Subject Satisfaction With Facial Appearance and Impact of Combined Facial TreatmentCompletedNCT04609020Phase 4

  Sponsor listed in the registry: Allergan · First submitted after Allergan became part of AbbVie

• JUVÉDERM® VOLUMA® With Lidocaine for Correction of Temple Hollowing in Chinese PopulationCompletedNCT04891419Phase 3

  Sponsor listed in the registry: Allergan · First submitted after Allergan became part of AbbVie

• Study to Assess Effectiveness and Adverse Events of JUVEDERM VOLBELLA With Lidocaine Injection in Correcting Infraorbital Hollowing in Chinese Adult ParticipantsCompletedNCT05088980Phase 3

  Sponsor listed in the registry: Allergan · First submitted after Allergan became part of AbbVie

• HArmonyCa Injectable Gel for Mid Face Soft Tissue AugmentationCompletedNCT05119777Phase 4

  Sponsor listed in the registry: Allergan · First submitted after Allergan became part of AbbVie

• Efficacy and Safety of a New Artificial Tear Formulation Compared With Systane Ultra Multidose in Participants With Dry Eye DiseaseCompletedNCT04393441Phase 3

  Sponsor listed in the registry: Allergan · First submitted after Allergan became part of AbbVie

• A Study of Armour® Thyroid Compared to Synthetic T4 (Levothyroxine) in Previously Hypothyroid ParticipantsCompletedNCT04124705Phase 2

  Sponsor listed in the registry: Allergan · First submitted before Allergan became part of AbbVie

• A Study Evaluating JUVÉDERM® VOLUMA® XC Injectable Gel for Correction of Temple Hollowing in Adult Participants ≥ 22 Years OldCompletedNCT04414397Phase 3

  Sponsor listed in the registry: Allergan · First submitted after Allergan became part of AbbVie

• Real-world Evidence Study of XEN in Chinese Patients With Refractory GlaucomaCompletedNCT04303897

  Sponsor listed in the registry: Allergan · First submitted before Allergan became part of AbbVie

• A Study to Evaluate Participant Satisfaction With Facial Appearance Overall and the Aesthetic and Psychosocial Impact of Combined Facial TreatmentCompletedNCT03712449Phase 4

  Sponsor listed in the registry: Allergan · First submitted before Allergan became part of AbbVie

• CoolSculpting® Elite for Non-Invasive Fat ReductionCompletedNCT04897867Phase 4

  Sponsor listed in the registry: Allergan · First submitted after Allergan became part of AbbVie

• Atogepant for Prophylaxis of Migraine in Participants Who Failed Previous Oral Prophylactic Treatments.CompletedNCT04740827Phase 3

  Sponsor listed in the registry: Allergan · First submitted after Allergan became part of AbbVie

• JUVÉDERM VOLUX® for Chin Retrusion in ChinaCompletedNCT04559984Phase 3

  Sponsor listed in the registry: Allergan · First submitted after Allergan became part of AbbVie

• AGN-151586 Dose-Ranging Study for Treatment of Glabellar LinesCompletedNCT04096326Phase 2

  Sponsor listed in the registry: Allergan · First submitted before Allergan became part of AbbVie

• International CoolSculpting: Study to Evaluate Patient Satisfaction for Non-Invasive Fat Reduction in Abdomen and/or Flanks (iCOOL)CompletedNCT03909100Not applicable

  Sponsor listed in the registry: Allergan · First submitted before Allergan became part of AbbVie

• Study to Assess Adverse Events (AEs) When Oral Atogepant Tablet is Given to Adult Chinese Participants Who Completed Study 3101-303-002 to Prevent Chronic MigraineCompletedNCT04829747Phase 3

  Sponsor listed in the registry: Allergan · First submitted after Allergan became part of AbbVie

• Safety and Effectiveness of the XEN45 Glaucoma Treatment System in Patients With Angle Closure GlaucomaCompletedNCT03362931Phase 3

  Sponsor listed in the registry: Allergan · First submitted before Allergan became part of AbbVie

• BOTOX® for the Treatment of Platysma ProminenceCompletedNCT03915067Phase 2

  Sponsor listed in the registry: Allergan · First submitted before Allergan became part of AbbVie

• Evaluation of OZURDEX® in Patients With Macular Edema Secondary to Retinal Vein Occlusion in ChinaCompletedNCT03908307Phase 4

  Sponsor listed in the registry: Allergan · First submitted before Allergan became part of AbbVie

• A Study to Assess Safety and Efficacy in Participants Age 40 to 55 With Presbyopia (Old Eye) Who Receive AGN-190584 in Both Eyes Twice DailyCompletedNCT04983589Phase 3

  Sponsor listed in the registry: Allergan · First submitted after Allergan became part of AbbVie

• A Study of JUVÉDERM VOLUX® Injectable Gel for Chin Enhancement in Chinese Adults Using Real-World EvidenceCompletedNCT04687046

  Sponsor listed in the registry: Allergan · First submitted after Allergan became part of AbbVie

• Efficacy, Safety, and Tolerability of Atogepant for the Prevention of Chronic MigraineCompletedNCT03855137Phase 3

  Sponsor listed in the registry: Allergan · First submitted before Allergan became part of AbbVie

• Study of the Safety and Effectiveness of JUVÉDERM VOLUX™ XC Injectable Gel for Restoring Jawline DefinitionCompletedNCT03712137Phase 3

  Sponsor listed in the registry: Allergan · First submitted before Allergan became part of AbbVie

• OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Overactive Bladder in Pediatric Patients (12 to 17)TerminatedNCT02097121Phase 3

  Sponsor listed in the registry: Allergan · First submitted before Allergan became part of AbbVie

• JUVÉDERM® VOLITE™ XC for Cheek Skin SmoothnessCompletedNCT03728309Not applicable

  Sponsor listed in the registry: Allergan · First submitted before Allergan became part of AbbVie

• A Study to Evaluate the Effect of Juvederm Volift With Lidocaine on Aging Hands in Participants Age 35 and OlderCompletedNCT04390581Phase 4

  Sponsor listed in the registry: Allergan · First submitted before Allergan became part of AbbVie

• VFORM: Prospective, Open Label, Study to Evaluate VOLIFT With Lidocaine Treatment for FORehead Contouring and Marionette LinesCompletedNCT05077488Phase 4

  Sponsor listed in the registry: Allergan · First submitted after Allergan became part of AbbVie

• A Study to Evaluate the Effectiveness and Safety of OZURDEX® in Patients With Diabetic Macular Edema But Never TreatedCompletedNCT03953807Phase 4

  Sponsor listed in the registry: Allergan · First submitted before Allergan became part of AbbVie

• Long Term Prospective Uncontrolled Study Of Earfold™ For The Treatment Of Prominent EarsCompletedNCT03194269Phase 4

  Sponsor listed in the registry: Allergan · First submitted before Allergan became part of AbbVie

• XEN-45 Gel Stent Versus Trabeculectomy in Glaucoma: Gold-Standard Pathway Study (GPS)CompletedNCT03654885Phase 4

  Sponsor listed in the registry: Allergan · First submitted before Allergan became part of AbbVie

• A Study to Evaluate Androderm®'s Effect on Blood Pressure in Adult Hypogonodal Male ParticipantsCompletedNCT04320745Phase 4

  Sponsor listed in the registry: Allergan · First submitted before Allergan became part of AbbVie

• Study of AGN-190584 Eye Drops to Assess Safety and Efficacy in Participants Aged 40-80 Years With Pseudophakic PresbyopiaWithdrawnNCT05393089Phase 2

  Sponsor listed in the registry: Allergan · First submitted after Allergan became part of AbbVie

• Extension Study to Evaluate the Long-Term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic MigraineCompletedNCT03939312Phase 3

  Sponsor listed in the registry: Allergan · First submitted before Allergan became part of AbbVie

• Linaclotide Safety and Efficacy in 2 to 5-Year-Old Participants With Functional ConstipationCompletedNCT04110145Phase 2

  Sponsor listed in the registry: Allergan · First submitted before Allergan became part of AbbVie

• Efficacy, Safety, and Tolerability of Levomilnacipran ER in Pediatric Patients (7-17 Years) With Major Depressive DisorderCompletedNCT03569475Phase 3

  Sponsor listed in the registry: Allergan · First submitted before Allergan became part of AbbVie

• A Comparison of Bimatoprost SR to Selective Laser Trabeculoplasty in Patients With Open-Angle Glaucoma or Ocular HypertensionCompletedNCT02636946Phase 3

  Sponsor listed in the registry: Allergan · First submitted before Allergan became part of AbbVie

• Evaluation of Age-related Skin Changes Using Clinical Probe Measurements and Imaging Modalities in Chinese SubjectsCompletedNCT04655300

  Sponsor listed in the registry: Allergan · First submitted after Allergan became part of AbbVie

• A Phase 3 Efficacy Study of Pilocarpine HCl Ophthalmic Solution (AGN-190584) in Participants With PresbyopiaCompletedNCT03857542Phase 3

  Sponsor listed in the registry: Allergan · First submitted before Allergan became part of AbbVie

• Efficacy Study of Pilocarpine HCl Ophthalmic Solution (AGN-190584) in Participants With PresbyopiaCompletedNCT03804268Phase 3

  Sponsor listed in the registry: Allergan · First submitted before Allergan became part of AbbVie

• A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis Study 03TerminatedNCT03420781Phase 3

  Sponsor listed in the registry: Allergan · First submitted before Allergan became part of AbbVie

• Diabetic Gastroparesis Study 05TerminatedNCT03786380Phase 3

  Sponsor listed in the registry: Allergan · First submitted before Allergan became part of AbbVie

• A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis Study 04TerminatedNCT03383146Phase 3

  Sponsor listed in the registry: Allergan · First submitted before Allergan became part of AbbVie

• Intradermal (ID) BOTOX in the Treatment of Facial Fine LinesCompletedNCT04631588Phase 1

  Sponsor listed in the registry: Allergan · First submitted after Allergan became part of AbbVie

• A Safety and Effectiveness of VOLBELLA XC Hyaluronic Acid (HA) Injectable Gel to Correct Infraorbital HollowingCompletedNCT03418545Phase 3

  Sponsor listed in the registry: Allergan · First submitted before Allergan became part of AbbVie

• Satisfaction With XEN Gel Stent Versus Trabeculectomy for the Treatment of GlaucomaCompletedNCT03852810

  Sponsor listed in the registry: Allergan · First submitted before Allergan became part of AbbVie